Identification and characterization of IMD-0354 as a glutamine carrier protein inhibitor in Melanoma

Yongmei Feng, Gaurav Pathria, Susanne Heynen-Genel, Michael Jackson, Brian James, Jun Yin, David A. Scott, Ze'ev A. Ronai

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

A key hallmark of cancer, altered metabolism, is central to cancer pathogenesis and therapy resistance. Robust glutamine metabolism is among cellular processes regulating tumor progression and responsiveness to therapy in a number of cancers, including melanoma and breast cancer. Among mechanisms underlying the increase in glutamine metabolism in tumors is enhanced glutamine uptake mediated by the glutamine transporters, with SLC1A5 (also known as ASCT2) shown to play a predominant role. Correspondingly, increased SLC1A5 expression coincides with poorer survival in patients with breast cancer and melanoma. Therefore, we performed an image-based screen to identify small molecules that are able to prevent the localization of SLC1A5 to the plasma membrane without impacting cell shape. From 7,000 small molecules, nine were selected as hits, of which one (IMD-0354) qualified for further detailed functional assessment. IMD-0354 was confirmed as a potent inhibitor of glutamine uptake that attained sustained low intracellular glutamine levels. Concomitant with its inhibition of glutamine uptake, IMD-0354 attenuated mTOR signaling, suppressed two- and three-dimensional growth of melanoma cells, and induced cell-cycle arrest, autophagy, and apoptosis. Pronounced effect of IMD-0354 was observed in different tumor-derived cell lines, compared with nontransformed cells. RNA-sequencing analysis identified the unfolded protein response, cell cycle, and response (DNA damage response pathways) to be affected by IMD-0354. Combination of IMD-0354 with GLS1 or LDHA inhibitors enhanced melanoma cell death. In vivo, IMD-0354 suppressed melanoma growth in a xenograft model. As a modulator of glutamine metabolism, IMD-0354 may serve as an important therapeutic and experimental tool that deserves further examination.

Original languageEnglish
Pages (from-to)816-832
Number of pages17
JournalMolecular Cancer Therapeutics
Volume20
Issue number5
DOIs
StatePublished - May 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Identification and characterization of IMD-0354 as a glutamine carrier protein inhibitor in Melanoma'. Together they form a unique fingerprint.

Cite this